Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial

Yan Zhao(University of California, Los Angeles), Jianzhong Zhang(Peking University), Litao Zhang(Tianjin University of Traditional Chinese Medicine)
Journal of the American Academy of Dermatology
July 20, 2024
Cited by 35


Related Papers